Symbiotec Pharmalab Limited
SYMBIOTEC • BSE, NSE
Issue details
Price band
₹938 - ₹988
Lot size
15 shares
Issue size
₹1296.74 Cr
Min. investment
₹14,820
Registrar
MUFG Intime India
Subscription
58.32x
Grey market premium
Est. gain+₹185 · 19%
Save your family's PANs once and check allotment for everyone the moment results are out.
Sign in with a mobile OTP. It takes 20 seconds.
IPO Timeline
Open
24 Aug
Close
27 Aug
Allotment
28 Aug
Listing
1 Sep
- Refunds & demat credit
- 29 Aug 2026
- Mandate end
- 11 Sep 2026
- Anchor lock-in 50%
- 27 Sep 2026
- Anchor lock-in 100%
- 26 Nov 2026
We calculate these dates from the allotment and close dates, so please treat them as indicative. Anchor lock-in applies only to issues with an anchor allotment.
Application size
| Category | Minimum | Maximum |
|---|---|---|
| RII | 15shares 1 lot · ₹14,820 | 195shares 13 lots · ₹1,92,660 |
| sNII (₹2L–₹10L) | 210shares 14 lots · ₹2,07,480 | 1,005shares 67 lots · ₹9,92,940 |
| bNII (above ₹10L) | 1,020shares 68 lots · ₹10,07,760 | No limit funds permitting |
Based on the upper price band of ₹988 and a lot of 15 shares.
Subscription
| Quota | Shares offered | Shares bid | Subscribed |
|---|---|---|---|
| NII | 28,04,904 | 17,89,41,090 | 63.80x |
| bNII (above ₹10L) | 9,34,968 | 3,95,01,195 | 42.25x |
| Retail (IND) | 65,44,776 | 5,40,99,315 | 8.27x |
| Total | 1,31,24,929 | 76,54,68,900 | 58.32x |
Last updated 14 days ago.
Issue structure
Face value
₹2 per share
Issue type
Bookbuilding IPO
Sale type
Fresh capital cum OFS
Fresh issue
₹150 Cr
15,21,261 shares
Offer for sale
₹1607 Cr
1,62,65,181 shares
Shares pre-issue
6,16,81,496
Shares post-issue
6,32,02,757
Valuation & ratios
| Metric | Pre-IPO | Post-IPO |
|---|---|---|
| EPS | 17.82 | 17.39 |
| P/E | 55.44 | 56.81 |
| Market cap | ₹6,094Cr. | ₹6,244.43 Cr |
| KPI | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| ROE | 11.19% | 12.66% |
| ROCE | 11.56% | 11.80% |
| RoNW | 9.48% | 11.79% |
| PAT Margin | 12.60% | 12.80% |
| EBITDA Margin | 26.59% | 27.26% |
| NAV | 184.69 | 150.17 |
| Price to Book Value | 5.35 | 6.58 |
Financials
| Metric | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Total income | 872.26 | 755.98 | 723.33 |
| Profit after tax | 109.9 | 96.79 | 100.06 |
| EBITDA | 231.97 | 206.11 | 177.04 |
| Net worth | 1,158.64 | 821.15 | 720.68 |
| Assets | 1,780.79 | 1,579.65 | 1,294.79 |
| Reserves & surplus | 1,145.95 | 810.03 | 709.54 |
| Total borrowing | 387.91 | 540.92 | 247.21 |
Figures in ₹ crore, as reported by the company in its offer document.
Objects of the issue
- 1.Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company₹112.5 Cr
- 2.General corporate purposes—
What the company says it intends to do with the money raised.
Recent comparable IPOs
| Company | Issue price | P/E | Listing close | Listing gain |
|---|---|---|---|---|
| Hexagon Nutrition Ltd.Mainboard | ₹45 | 22.69 | ₹53.19 | +18.20% |
| Sai Parenteral's Ltd.Mainboard | ₹392 | 72.19 | ₹405.70 | +3.49% |
| Corona Remedies Ltd.Mainboard | ₹1062 | 43.47 | ₹1,438.40 | +35.44% |
| Rubicon Research Ltd.Mainboard | ₹485 | 55.75 | ₹628.20 | +29.53% |
| Amanta Healthcare Ltd.Mainboard | ₹126 | 34.59 | ₹141.75 | +12.50% |
| Anlon Healthcare Ltd.Mainboard | ₹91 | 17.67 | ₹91.73 | +0.80% |
| Bio Medica Laboratories Ltd.SME | ₹139 | 13.03 | ₹115.80 | -16.69% |
| Goldline Pharmaceutical Ltd.SME | ₹43 | 10.47 | ₹56.77 | +32.02% |
| Speciality Medicines Ltd.SME | ₹124 | 9.27 | ₹125.90 | +1.53% |
| Accretion Nutraveda Ltd.SME | ₹129 | 26.27 | ₹191.20 | +48.22% |
| KRM Ayurveda Ltd.SME | ₹135 | 17.32 | ₹180.70 | +33.85% |
| Curis Lifesciences Ltd.SME | ₹128 | 12.44 | ₹141.00 | +10.16% |
| Aptus Pharma Ltd.SME | ₹70 | 11.29 | ₹84.84 | +21.20% |
Past listing performance of comparable issues. This is not a forecast: listing gains vary widely and can turn negative.
Issue fundamentals compiled from the company's offer document via Chittorgarh, last read 19 Aug 2026. Always verify against the RHP before applying.